Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of 26.32% and 54.06%, respectively, for the quarter ended June 2023. Do the…
1,339€
3,16%
Echtzeit-Aktienkurs Editas Medicine Inc.
Bid:
Ask:
Nachrichten zur Editas Medicine Inc. Aktie
Form 8-K Editas Medicine, Inc. For: Aug 02
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas, Azzur expand manufacturing partnership
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company,…
Is Editas Medicine Stock a Buy Now?
The fortunes of this once-promising biotech company have changed in the past year....…
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
Its not about to start making money anytime soon....…
Form 8-K Editas Medicine, Inc. For: Jun 14
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Shares Fall 15% on Pricing of Secondary Stock Offering
Editas Medicine Shares Fall 15% on Pricing of Secondary Stock Offering...…
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately....…
Editas Medicine down 6%, prices $125M offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Announces Pricing of Offering of Common Stock
CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company,…
Stocks to Watch: Ammo, Editas Medicine
Stocks to Watch: Ammo, Editas Medicine...…
Editas Medicine Shares Sink 5.7% after Secondary Stock Offering
Editas Medicine Shares Sink 5.7% after Secondary Stock Offering...…
Editas Medicine shares slip after proposing $125M stock offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Announces Offering of Common Stock
CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company,…
Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains?
Editas (EDIT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…
What 6 Analyst Ratings Have To Say About Editas Medicine
Latest Ratings for EDIT
DateFirmActionFromTo Feb 2022OppenheimerMaintainsOutperform Feb 2022Chardan CapitalMaintainsBuy Feb 2022SVB LeerinkMaintainsMarket Perform
View…
Editas upgraded to overweight at Raymond James on sickle cell candidate
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies
Editas (EDIT) announces positive preliminary safety and efficacy data from patients treated with its lead drug, EDIT-301, in the RUBY…
Editas posts initial data for gene editing candidate for blood disorders
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Editas Medicine, Inc. For: Jun 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant...…
Insiderhandel: CEO verkauft Aktien von Editas Medicine im Wert von 61.638$
Oneill, Gilmore Neil - Vorstand - Tag der Transaktion: 2023-06-05...…
Form 8-K Editas Medicine, Inc. For: Jun 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today…
Editas Medicine appoints Erick Lucera as CFO, Michelle Robertson steps down
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Michelle Robertson to remain with Company until August 16, 2023 Michelle Robertson to remain with Company until August 16, 2023...…
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
Company-sponsored webinar to be announced Company-sponsored webinar to be announced...…
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up
Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates…
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of 10.13% and 97.42%, respectively, for the quarter ended March 2023. Do the…
Form 8-K Editas Medicine, Inc. For: May 05
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Announces First Quarter 2023 Results and Business Updates
Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European…
Editas Medicine Q1 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company,…
GeneTether Therapeutics Engages Gad Berdugo, Managing Partner of Explorium Capital LLC, as Advisor to Explore Strategic Alternatives for GeneTether Technology Platform
Vancouver, British Columbia – TheNewswire - May 1st, 2023 - GeneTether Therapeutics Inc. (“GeneTether” or the “Company”) (CSE:GTTX), is pleased…
Editas sickle cell candidate granted FDA Orphan Drug designation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Gets Orphan Drug Designation for EDIT-301
Editas Medicine Gets Orphan Drug Designation for EDIT-301...…
Earnings Preview: Editas Medicine (EDIT) Q1 Earnings Expected to Decline
Editas (EDIT) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Why Shares of Editas Medicine Rose Monday
The company is benefiting from positive news affecting other gene-editing stocks....…
Editas (EDIT) Soars 20.3%: Is Further Upside Left in the Stock?
Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
Form 8-K Editas Medicine, Inc. For: Apr 11
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine strengthens board of directors with appointment of new chair and new director
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
Emma Reeve to support Editas evolution in new role as Chair of the Board...…
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Neither stock is a good choice for those who cant handle a lot of risk....…
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future....…
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It
Editas Medicine is a high-risk stock with the potential of a big reward....…
Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus
Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected…
Editas rises on Q4 revenue beat, gene-editing therapy data for sickle cell disease by mid-year
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -4.76% and 43.33%, respectively, for the quarter ended December 2022. Do the…